암 진단 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 제품 유형별, 용도별, 최종 용도별, 검사 유형별, 대상 범위별, 지역별, 부문별 예측(2025-2030년)

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is anticipated to reach USD 155.07 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.14% from 2025 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

• Based on product, the consumables segment held the largest share of 58.4% in 2024 and is anticipated to grow at the fastest growth rate over the forecast period
• Based on type, in vitro diagnostics (IVD) segment dominated the in 2024 with a share of 52.0% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
• The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
• Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
• The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
• North America dominated the global cancer diagnostics market in 2024, owing to rise in the number of approvals of new diagnostic tests
• The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. List Of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product And Type Snapshot
• 2.3. Application And End Use Snapshot
• 2.4. Test Type And Coveragesnapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation And Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Rising Prevalence Of Cancer
  • 3.4.2. Technological Advancements
  • 3.4.3. Rising Initiatives Undertaken By Public And Private Organizations
  • 3.4.4. Extensive R&d For The Development Of Novel Testing Solutions
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost Of Diagnostic Imaging
  • 3.5.2. Radiation Exposure Likely To Limit Usage Of Ct Scans
  • 3.5.3. Rising Adoption Of Refurbished Diagnostic Imaging Systems
• 3.6. Business Environment Analysis
  • 3.6.1. Swot Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
  • 3.6.3. Covid-19 Impact Analysis
• 3.7. Market Opportunity Analysis
  • 3.7.1. Advent Of Personalized Medicine And Companion Diagnostics
• 3.8. Artificial Intelligence Landscape For Cancer Diagnostics
  • 3.8.1. Market Trends:
  • 3.8.2. New Product Development
  • 3.8.3. List Of Key Players With Their Offerings
• 3.9. Comparative Analysis Of Solid Vs. Liquid Biopsies
• 3.10. Trends In Blood-based Diagnostics
• 3.11. Cfdna Test Landscape
  • 3.11.1. Approved Tests
  • 3.11.2. Clinical Trials Landscape
• 3.12. Ngs Tests Landscape
• 3.13. Trends In Early Detection
  • 3.13.1. Early Detection In Asymptomatic Patients
  • 3.13.2. Symptomatic Patients
  • 3.13.3. Recurrence Detection
• 3.14. U.S. Cancer Research Grants Funding Landscape
  • 3.14.1. By Cancer Type
  • 3.14.2. By State
• 3.15. Patent Filing Landscape
• 3.16. Qualitative Analysis Of How Upcoming Technologies Fit Into Patient Pathways

Chapter 4. Product Business Analysis

• 4.1. Cancer Diagnostics Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.2. Pathology Based-instruments
    • 4.2.2.1. Slide Staining Systems
      • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.2. Tissue Processing Systems
      • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.3. Cell Processors
      • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.4. Pcr Instruments
      • 4.2.2.4.1. Pcr Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.5. Ngs Instruments
      • 4.2.2.5.1. Ngs Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.6. Microarrays
      • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 4.2.2.7. Other Pathology-based Instruments
      • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.3. Imaging Instruments
  • 4.2.4. Others
• 4.3. Consumables
  • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

• 5.1. Cancer Diagnostics Market: Type Movement Analysis
• 5.2. IVD
  • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
  • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
    • 5.2.2.1. Diagnosis
      • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
    • 5.2.2.2. Early Detection
      • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.3. Therapy Selection
      • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.4. Monitoring
      • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
  • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
    • 5.2.3.1. Polymerase Chain Reaction (Pcr)
      • 5.2.3.1.1. Polymerase Chain Reaction (Pcr) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.2. In Situ Hybridization (Ish)
      • 5.2.3.2.1. In Situ Hybridization (Ish) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.3. Immunohistochemistry (Ihc)
      • 5.2.3.3.1. Immunohistochemistry (Ihc) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.4. Next-generation Sequencing (Ngs)
      • 5.2.3.4.1. Next-generation Sequencing (Ngs) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.5. Microarrays
      • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.6. Flow Cytometry
      • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
    • 5.2.3.7. Immunoassays
      • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.8. Other IVD Testing Technologies
      • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
• 5.3. LDT
  • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
• 5.4. Imaging
  • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
  • 5.4.2. Magnetic Resonance Imaging (Mri)
    • 5.4.2.1. Magnetic Resonance Imaging (Mri) Market, 2018 - 2030 (USD Billion)
  • 5.4.3. Computed Tomography (Ct)
    • 5.4.3.1. Computed Tomography (Ct) Market, 2018 - 2030 (USD Billion)
  • 5.4.4. Positron Emission Tomography (Pet)
    • 5.4.4.1. Positron Emission Tomography (Pet) Market, 2018 - 2030 (USD Billion)
  • 5.4.5. Mammography
    • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
  • 5.4.6. Ultrasound
    • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

• 6.1. Cancer Diagnostics Market: Application Movement Analysis
• 6.2. Breast Cancer
  • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
• 6.3. Colorectal Cancer
  • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
• 6.4. Cervical Cancer
  • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
• 6.6. Prostate Cancer
  • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
• 6.7. Skin Cancer
  • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
• 6.8. Blood Cancer
  • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
• 6.9. Kidney Cancer
  • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
• 6.10. Liver Cancer
  • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
• 6.11. Pancreatic Cancer
  • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
• 6.12. Ovarian Cancer
  • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
• 6.13. Others
  • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End Use Business Analysis

• 7.1. Cancer Diagnostics Market: End Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 7.3. Laboratories
  • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
• 7.4. Others
  • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

• 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
• 8.2. Biopsy
  • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.2. Fine-needle Aspiration
    • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
  • 8.2.3. Core Biopsy
    • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.4. Surgical Biopsy
    • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.5. Skin Biopsy /punch Biopsy
    • 8.2.5.1. Skin Biopsy /punch Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.6. Others
    • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
• 8.3. Others
  • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

• 9.1. Cancer Diagnostics Market: Product Movement Analysis
• 9.2. Instruments
  • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
• 9.3. Consumables Kits And Reagents
  • 9.3.1. Consumables Kits And Reagents Market, 2018 - 2030 (USD Billion)
• 9.4. Software And Services
  • 9.4.1. Software And Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Coverage Business Analysis

• 10.1. Cancer Diagnostics Market: Coverage Movement Analysis
• 10.2. Public Insurance
  • 10.2.1. Public Insurance Market, 2018 - 2030 (USD Billion)
• 10.3. Private Insurance
  • 10.3.1. Private Insurance Market, 2018 - 2030 (USD Billion)

Chapter 11. Regional Business Analysis

• 11.1. Cancer Diagnostics Market Share By Region, 2024 & 2030
• 11.2. North America
  • 11.2.1. North America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.3. Europe
  • 11.3.1. Europe Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.3. Uk
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. Uk Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.5. Latin America
  • 11.5.1. Latin America Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.3. Mexico
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Mexico Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.5.4. Argentina
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Target Disease Prevalence
    • 11.5.4.3. Competitive Scenario
    • 11.5.4.4. Regulatory Framework
    • 11.5.4.5. Reimbursement Scenario
    • 11.5.4.6. Argentina Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
• 11.6. Mea
  • 11.6.1. Mea Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.4. Uae
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. Uae Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 12. Competitive Landscape

• 12.1. Company Categorization
• 12.2. Cancer Diagnostics Market Share Analysis, 2024
• 12.3. Company Profiles
  • 12.3.1. Abbott
    • 12.3.1.1. Company Overview
    • 12.3.1.2. Financial Performance
    • 12.3.1.3. Product Benchmarking
    • 12.3.1.4. Strategic Initiatives
  • 12.3.2. Ge Healthcare
    • 12.3.2.1. Company Overview
    • 12.3.2.2. Financial Performance
    • 12.3.2.3. Product Benchmarking
    • 12.3.2.4. Strategic Initiatives
  • 12.3.3. F. Hoffmann-la Roche Ltd.
    • 12.3.3.1. Company Overview
    • 12.3.3.2. Financial Performance
    • 12.3.3.3. Product Benchmarking
    • 12.3.3.4. Strategic Initiatives
  • 12.3.4. Qiagen
    • 12.3.4.1. Company Overview
    • 12.3.4.2. Financial Performance
    • 12.3.4.3. Product Benchmarking
    • 12.3.4.4. Strategic Initiatives
  • 12.3.5. Bd
    • 12.3.5.1. Company Overview
    • 12.3.5.2. Financial Performance
    • 12.3.5.3. Product Benchmarking
    • 12.3.5.4. Strategic Initiatives
  • 12.3.6. Siemens Healthcare Gmbh
    • 12.3.6.1. Company Overview
    • 12.3.6.2. Financial Performance
    • 12.3.6.3. Product Benchmarking
    • 12.3.6.4. Strategic Initiatives
  • 12.3.7. Thermo Fisher Scientific, Inc.
    • 12.3.7.1. Company Overview
    • 12.3.7.2. Financial Performance
    • 12.3.7.3. Product Benchmarking
    • 12.3.7.4. Strategic Initiatives
  • 12.3.8. Hologic, Inc.
    • 12.3.8.1. Company Overview
    • 12.3.8.2. Financial Performance
    • 12.3.8.3. Product Benchmarking
    • 12.3.8.4. Strategic Initiatives
  • 12.3.9. Koninklijke Philips N.v. (Philips)
    • 12.3.9.1. Company Overview
    • 12.3.9.2. Financial Performance
    • 12.3.9.3. Product Benchmarking
    • 12.3.9.4. Strategic Initiatives
  • 12.3.10. Illumina, Inc.
    • 12.3.10.1. Company Overview
    • 12.3.10.2. Financial Performance
    • 12.3.10.3. Product Benchmarking
    • 12.3.10.4. Strategic Initiatives
  • 12.3.11. Agilent Technologies Inc
    • 12.3.11.1. Company Overview
    • 12.3.11.2. Financial Performance
    • 12.3.11.3. Product Benchmarking
    • 12.3.11.4. Strategic Initiatives
  • 12.3.12. Foundation Medicine
    • 12.3.12.1. Company Overview
    • 12.3.12.2. Financial Performance
    • 12.3.12.3. Product Benchmarking
    • 12.3.12.4. Strategic Initiatives
  • 12.3.13. Danaher Corporation
    • 12.3.13.1. Company Overview
    • 12.3.13.2. Financial Performance
    • 12.3.13.3. Product Benchmarking
    • 12.3.13.4. Strategic Initiatives
  • 12.3.14. Bio-rad Laboratories, Inc
    • 12.3.14.1. Company Overview
    • 12.3.14.2. Financial Performance
    • 12.3.14.3. Product Benchmarking
    • 12.3.14.4. Strategic Initiatives
  • 12.3.15. Perkinelmer Inc
    • 12.3.15.1. Company Overview
    • 12.3.15.2. Financial Performance
    • 12.3.15.3. Product Benchmarking
    • 12.3.15.4. Strategic Initiatives
  • 12.3.16. Myriad Genetics, Inc.
    • 12.3.16.1. Company Overview
    • 12.3.16.2. Financial Performance
    • 12.3.16.3. Product Benchmarking
    • 12.3.16.4. Strategic Initiatives
  • 12.3.17. Sysmex Corporation
    • 12.3.17.1. Company Overview
    • 12.3.17.2. Financial Performance
    • 12.3.17.3. Product Benchmarking
    • 12.3.17.4. Strategic Initiatives
  • 12.3.18. Neogenomics Laboratories, Inc
    • 12.3.18.1. Company Overview
    • 12.3.18.2. Financial Performance
    • 12.3.18.3. Product Benchmarking
    • 12.3.18.4. Strategic Initiatives
  • 12.3.19. Exact Sciences Corporation
    • 12.3.19.1. Company Overview
    • 12.3.19.2. Financial Performance
    • 12.3.19.3. Product Benchmarking
    • 12.3.19.4. Strategic Initiatives
  • 12.3.20. Grail
    • 12.3.20.1. Company Overview
    • 12.3.20.2. Financial Performance
    • 12.3.20.3. Product Benchmarking
    • 12.3.20.4. Strategic Initiatives
  • 12.3.21. Guardant Health Inc,.
    • 12.3.21.1. Company Overview
    • 12.3.21.2. Financial Performance
    • 12.3.21.3. Product Benchmarking
    • 12.3.21.4. Strategic Initiatives
  • 12.3.22. Tempus
    • 12.3.22.1. Company Overview
    • 12.3.22.2. Financial Performance
    • 12.3.22.3. Product Benchmarking
    • 12.3.22.4. Strategic Initiatives
  • 12.3.23. Delfi Diagnostics
    • 12.3.23.1. Company Overview
    • 12.3.23.2. Financial Performance
    • 12.3.23.3. Product Benchmarking
    • 12.3.23.4. Strategic Initiatives
  • 12.3.24. Adela, Inc
    • 12.3.24.1. Company Overview
    • 12.3.24.2. Financial Performance
    • 12.3.24.3. Product Benchmarking
    • 12.3.24.4. Strategic Initiatives
  • 12.3.25. Clearnote Health
    • 12.3.25.1. Company Overview
    • 12.3.25.2. Financial Performance
    • 12.3.25.3. Product Benchmarking
    • 12.3.25.4. Strategic Initiatives
  • 12.3.26. Natera
    • 12.3.26.1. Company Overview
    • 12.3.26.2. Financial Performance
    • 12.3.26.3. Product Benchmarking
    • 12.3.26.4. Strategic Initiatives
• 12.4. Strategy Mapping
  • 12.4.1. Expansion
  • 12.4.2. Acquisition
  • 12.4.3. Collaborations
  • 12.4.4. Disease Type/drug Class Launch
  • 12.4.5. Partnerships
  • 12.4.6. Others
• 12.5. Distribution Model Analysis For Major Players
• 12.6. Competitive Heat Map Analysis For U.S. Cancer Diagnostics Market, 2024
• 12.7. Competitive Heat Map Analysis For Uk Cancer Diagnostics Market, 2024
• 12.8. List Of Cancers Of Unknown Primary Diagnostics Companies
• 12.9. Guardant Test Evaluation

Chapter 13. Conclusion/key Takeways